{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":2,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03487016\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FOOTPATH","nct_id":"NCT03487016","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=footpath-nct03487016. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"FOOTPATH","arms":[{"description":"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.\n\nTreatment is given until disease progression or the occurrence of unacceptable toxicity.","label":"A: Gemcitabine/nab-Paclitaxel (Standard)","type":"ACTIVE_COMPARATOR"},{"description":"On Day 1 of a 14-day cycle:\n\nLiposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)\n\nTreatment is given until disease progression or the occurrence of unacceptable toxicity.","label":"B: NAPOLI regimen","type":"EXPERIMENTAL"},{"description":"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.\n\nNAPOLI:\n\nOn Day 1 of a 14-day cycle:\n\nLiposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)\n\nmFOLFOX6:\n\nOn Day 1 of a 14-day cycle:\n\nOxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)\n\nTreatment is given until disease progression or the occurrence of unacceptable toxicity.","label":"C: seq-NAPOLI-FOLFOX","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-07","type":"ESTIMATED"},"conditions":["Metastatic Pancreatic Cancer"],"enrollment":{"count":270,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Gemcitabine","type":"DRUG"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"5-FU","type":"DRUG"},{"name":"Irinotecan Liposomal Injection","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2022-09-08","lead_sponsor":"Ludwig-Maximilians - University of Munich","official_title":"A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2022-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"60 months"}],"references":[],"start_date":{"date":"2019-02-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"First-line Therapy in Metastatic PDAC","url":"https://clinicaltrials.gov/study/NCT03487016"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/footpath-nct03487016"}